|Articles|December 16, 2013

BioPharm International-12-16-2013
Volume 2013 eBook
Issue 1

Leveraging Development Strengths Drives Therapies to Market

NPS Pharmaceuticals uses its expertise in development, regulatory compliance, and commercialization to bring to market products with orphan drug status.

Established biopharmaceutical company NPS Pharmaceuticals uses its expertise in development, regulatory compliance, and commercialization to bring to market products with orphan drug status.

Read this article from BioPharm International’s 2013 Innovation Updates and Strategies eBook.

View other articles in the 2013 Innovation Updates and Strategies eBook.

Articles in this issue

almost 13 years ago

Article

Creating Better Medicines through Better Conjugation

almost 13 years ago

Article

Recovering Patent Life with Patent Term Extension

almost 13 years ago

Article

Strategic Outsourcing in Clinical Development

almost 13 years ago

Article

Driving Innovation in Biopharmaceuticals

almost 13 years ago

Article

Crowdfunding Biopharmaceutical Innovation

almost 13 years ago

Article

Restructuring for Biopharmaceutical Success

Stay at the forefront of biopharmaceutical innovation. Subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related to this article

FDA - US Food and Drug Administration | Image credit: © gguy - © gguy - stock.adobe.com

October 1st, 2026

FDA Warns Fresenius Kabi Over Sterile Injectable Contamination

Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.

FDA headquarters at White Oak Campus in Silver Spring, Maryland, USA - January 13, 2020. The United States Food and Drug Administration (FDA) is a federal agency. | Image credit: © JHVEPhoto - © JHVEPhoto - stock.adobe.com

September 23rd, 2026

FDA Formalizes Non-Animal Testing Methods in New Rule

FDA's new rule formally recognizes non-animal methods like organoids and AI models as valid ways to support human drug testing.

A disposable syringe is filled with a clear liquid and lies on a metal table. Disposable syringe with three glass vials of medicines. 3d render. | Image credit: © Alexandr - © Alexandr - stock.adobe.com

September 30th, 2026

Teva's Denosumab-Adet (Degevma) Approved as Xgeva Biosimilar

Denosumab-adet now covers all 3 Xgeva indications, widening lower-cost treatment access for cancer patients with bone complications.

Regenerative medicine and therapeutic stem cell therapy to regrow damaged cells as treatment for disease as multicellular organisms for cellular treatment of injury or arthritis illness due to aging | Image credit: © freshidea - © freshidea - stock.adobe.com

September 29th, 2026

iRegene's NouvSight001 Cleared for US and China RP Trials

NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.

3D Rendering of Antibody Drug Conjugate Molecules - ADC - with cytotoxic payload | Image credit: © Alpha Tauri 3D - © Alpha Tauri 3D - stock.adobe.com

September 28th, 2026

Daiichi Sankyo, Merck Pull Ifinatamab Deruxtecan BLA in SCLC

Daiichi Sankyo and Merck pulled ifinatamab deruxtecan's FDA filing in small cell lung cancer after a 187-patient trial fell short.

Scientist Examining Medical Documents Near Ampoules and Pills | Image Credit: ©PixelPulse-stock.adobe.com

September 28th, 2026

IPEC’s EIP: A Standardized Communication Platform for Sharing Excipient Information as an Alternative to Questionnaires

IPEC’s EIP user guide streamlines information exchange and response times while increasing accuracy through standardization.

Weight loss and diabetes treatment. Person using Mounjaro insulin injector pen or GLP-1 injection for shot in abdomen. Obesity therapy, hormonal medication, semaglutide injection, modern healthcare | Image credit: © Corona Borealis - © Corona Borealis - stock.adobe.com

September 28th, 2026

FDA Approves Lilly's Insulin Efsitora Alfa-Gobe (Onswik) for Type 2 Diabetes

Insulin efsitora alfa-gobe (Onswik) cuts injections from 365 to 52 a year for adults with type 2 diabetes, per its new FDA approval.

3D X-ray-style illustration of a human torso with the kidneys, ureters, bladder, and urethra highlighted in orange against a blue background. | Image Credit: © Matthieu - stock.adobe.com

September 25th, 2026

FDA Grants Priority Review to Perioperative Imfinzi Plus Enfortumab Vedotin in Cisplatin-Ineligible Bladder Cancer

AstraZeneca's sBLA for durvalumab combined with neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer, based on the Phase 3 VOLGA trial, has a PDUFA date expected in the fourth quarter of 2026.